Table 4.
Effect of SSRI use on subsequent development of IBD activity and according to anxiety and depression scores at baseline.
| SSRI Use: All Patients | SSRI Use: Normal Anxiety and Depression Scores at Baseline | SSRI use: Abnormal Anxiety or Depression Scores at Baseline | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No | Yes | P Value | No | Yes | P value | No | Yes | P value | |
| Glucocorticosteroid prescription or flare of disease activity (%) | 121/279 (43.4) |
14/33 (42.4) |
0.92 | 82/203 (40.4) |
6/13 (46.2) |
0.68 | 38/73 (52.1) |
8/20 (40.0) |
0.34 |
|
| |||||||||
| Escalation of medical therapy in response to uncontrolled disease activity (%) | 120/279 (43.0) |
10/33 (30.3) |
0.16 | 85/203 (41.9) |
5/13 (38.5) |
0.81 | 34/73 (46.6) |
5/20 (25.0) |
0.08 |
|
| |||||||||
| Hospitalisation due to disease activity (%) | 38/279 (13.6) |
2/33 (6.1) |
0.22 | 26/203 (12.8) |
2/13 (15.4) |
0.79 | 12/73 (16.4) |
0/20 (0) |
0.05 |
|
| |||||||||
| Intestinal resection (%) | 15/279 (5.4) |
2/33 (6.1) |
0.87 | 8/203 (3.9) |
2/13 (15.4) |
0.06 | 7/73 (9.6) |
0/20 (0) |
0.15 |
|
| |||||||||
| Any adverse outcome (%) | 148/279 (53.0) |
14/33 (42.4) |
0.25 | 102/203 (50.2) |
6/13 (46.2) |
0.78 | 45/73 (61.6) |
8/20 (40.0) |
0.08 |